{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T19:10:37Z","timestamp":1719515437440},"reference-count":49,"publisher":"Georg Thieme Verlag KG","issue":"07\/08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Entwicklung neuer Therapien zur Behandlung der Alzheimer-Krankheit ist ein\n                    Fokus der weltweiten Arzneimittelforschung. Es wird an potenteren Therapien zur\n                    symptomatischen Behandlung, insbesondere zur Behandlung von\n                    Verhaltensst\u00f6rungen, aber auch an Medikamenten, die in die\n                    Pathophysiologie der Erkrankung eingreifen, geforscht, mit dem Ziel, das\n                    Voranschreiten der Alzheimer-Krankheit aufzuhalten oder zumindest zu\n                    verlangsamen. Dazu verlagert sich der Schwerpunkt der Identifikation von\n                    Menschen mit Alzheimer-Krankheit in Stadien der Pr\u00e4-Demenz wie das der\n                    leichten kognitiven St\u00f6rung (Mild Cognitive Impairment, MCI oder nahezu\n                    gleichbedeutend beginnende Alzheimer-Demenz: prodromal AD) oder gar in\n                    asymptomatische Stadien. Bisher ermutigendste Ergebnisse liegen f\u00fcr den\n                    Ansatz der passiven Immunisierung mittels monoklonaler Antik\u00f6rper gegen\n                    A\u03b242 vor. Bisher gelang es nicht, mit mehreren abgeschlossenen\n                    zulassungsrelevanten Studien statistisch signifikante Unterschiede auf den\n                    prim\u00e4ren Zielparametern zu demonstrieren. Der Antik\u00f6rper gegen\n                    Amyloid Aducanumab erhielt, basierend auf der Reduktion von Amyloid, eine\n                    vorl\u00e4ufige Zulassung mit Auflagen in den USA; das Zulassungsverfahren\n                    f\u00fcr Europa ist noch im Gange. Die gegenw\u00e4rtigen\n                    pharmakologischen Ans\u00e4tze zur Behandlung der Alzheimer-Krankheit bieten\n                    einen begrenzten symptomatischen Nutzen. Bisher ist noch keine\n                    verlaufsverz\u00f6gernde Behandlung gegen die Alzheimer-Krankheit in\n                    Deutschland auf dem Markt. Daher ist zu empfehlen, Patienten, insbesondere in\n                    pr\u00e4-dementiellen Stadien oder im Stadium der beginnenden\n                    Alzheimer-Demenz, eine Teilnahme an klinischen Studien zu empfehlen, um die\n                    Entwicklung von neuen und besser wirksamen Medikamenten zur Behandlung der\n                    Alzheimer-Krankheit, die dann vielen Patienten zu Gute kommen k\u00f6nnen, zu\n                    beschleunigen.<\/jats:p>","DOI":"10.1055\/a-1802-4837","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T22:47:11Z","timestamp":1653000431000},"page":"352-360","source":"Crossref","is-referenced-by-count":0,"title":["Therapieentwicklungen bei der Alzheimer-Krankheit"],"prefix":"10.1055","volume":"90","author":[{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[{"name":"Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen\n                    Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"ref1","first-page":"451","article-title":"Medikamente zur Behandlung der Alzheimer Krankheit in der Entwicklung. In:\n                    Jessen F, editor. Handbuch Alzheimer-Krankheit Grundlagen \u2013 Diagnostik\n                    \u2013 Therapie \u2013 Versorgung \u2013 Pr\u00e4vention","author":"T Grimmer","year":"2018","journal-title":"De Gruyter"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized Placebo-Controlled Trial of Nabilone for Agitation in\n                    Alzheimer\u2019s Disease","volume":"27","author":"N Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer\n                    Disease Dementia: A Randomized Clinical Trial","volume":"314","author":"J L Cummings","year":"2015","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable\n                    Alzheimer\u2019s disease dementia and insomnia: a randomized trial","volume":"16","author":"W J Herring","year":"2020","journal-title":"Alzheimers Dement"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/JAD-160017","article-title":"A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer\u2019s\n                    Disease","volume":"54","author":"A M Lozano","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"ref6","first-page":"832","article-title":"Current immune therapy for Alzheimer\u2019s disease","volume":"79","author":"T Grimmer","year":"2008","journal-title":"Nervenarzt"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nri1843","article-title":"Immunology and immunotherapy of Alzheimer\u2019s disease","volume":"6","author":"H L Weiner","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A\u00df peptide immunization reduces behavioural impairment and plaques in a\n                    model of Alzheimer\u2019s disease","volume":"408","author":"C Janus","year":"2000","journal-title":"nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"Abeta peptide vaccination prevents memory loss in an animal model of\n                    Alzheimer\u2019s disease","volume":"408","author":"D Morgan","year":"2000","journal-title":"nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u00df attenuates Alzheimer-disease-like pathology\n                    in the PDAPP mouse","volume":"400","author":"D Schenk","year":"1999","journal-title":"nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u00df-peptide enter the\n                    central nervous system and reduce pathology in a mouse model of Alzheimer\n                    disease","volume":"6","author":"F Bard","year":"2000","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic A\u00df42 (AN1792)\n                    in patients with AD","volume":"64","author":"A J Bayer","year":"2005","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an\n                    interrupted trial","volume":"64","author":"S Gilman","year":"2005","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42\n                    immunization","volume":"61","author":"J M Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","article-title":"Neuropathology and pathogenesis of encephalitis following amyloid-beta\n                    immunization in Alzheimer\u2019s disease","volume":"14","author":"I Ferrer","year":"2004","journal-title":"Brain Pathol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta\n                    peptide: a case report","volume":"9","author":"J A Nicoll","year":"2003","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1474-4422(03)00634-3","article-title":"Update on Elan vaccine for Alzheimer\u2019s disease","volume":"3","author":"L Spinney","year":"2004","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1750-3639.2008.00134.x","article-title":"The Role of the Immune System in Clearence of A\u00df from the Brain","volume":"18","author":"D Boche","year":"2008","journal-title":"Brain Pathol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease:\n                    follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"C Holmes","year":"2008","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate\n                    Alzheimer disease","volume":"73","author":"S Salloway","year":"2009","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s\n                    disease","volume":"370","author":"S Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s\n                    disease","volume":"370","author":"R S Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0b013e3181e396ea","article-title":"Incidence of cerebral microbleeds: a longitudinal study in a memory clinic\n                    population","volume":"74","author":"J D Goos","year":"2010","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s\n                    disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"R Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with\n                    Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind,\n                    placebo-controlled, ascending-dose study","volume":"9","author":"J O Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with\n                    gantenerumab","volume":"69","author":"S Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s\n                    disease","volume":"8","author":"M Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s\n                    disease","volume":"537","author":"J Sevigny","year":"2016","journal-title":"nature"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early\n                    Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril\n                    antibody","volume":"13","author":"C J Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding\n                    properties promotes neuroprotection and glial engulfment of Abeta","volume":"32","author":"O Adolfsson","year":"2012","journal-title":"J Neurosci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited\n                    Alzheimer\u2019s disease","volume":"27","author":"S Salloway","year":"2021","journal-title":"Nat Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer\u2019s\n                    disease with a protofibril selective Abeta antibody","volume":"8","author":"V Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer\u2019s\n                    disease patients","volume":"12","author":"E R Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1074\/jbc.M114.586602","article-title":"A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid\n                    beta in the brain in a transgenic model of Alzheimer disease","volume":"290","author":"Y Hori","year":"2015","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00784-020-03764-w","article-title":"Relationship of Porphyromonas gingivalis and Alzheimer\u2019s disease: a\n                    systematic review of pre-clinical studies","volume":"25","author":"MJ F Costa","year":"2021","journal-title":"Clin Oral Investig"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41593-019-0372-9","article-title":"Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell\n                    senescence and cognitive deficits in an Alzheimer\u2019s disease model","volume":"22","author":"P Zhang","year":"2019","journal-title":"Nat Neurosci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-020-00678-3","article-title":"A phase II randomized trial of sodium oligomannate in Alzheimer\u2019s\n                    dementia","volume":"12","author":"T Wang","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-021-00795-7","article-title":"A 36-week multicenter, randomized, double-blind, placebo-controlled,\n                    parallel-group, phase 3 clinical trial of sodium oligomannate for\n                    mild-to-moderate Alzheimer\u2019s dementia","volume":"13","author":"S Xiao","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-131535","article-title":"Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load\n                    and cognitive decline in Alzheimer\u2019s disease","volume":"39","author":"M Morawski","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ajpath.2013.05.005","article-title":"Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human\n                    primates, canines, and Alzheimer disease-like transgenic mouse models","volume":"183","author":"J L Frost","year":"2013","journal-title":"Am J Pathol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in\n                    Alzheimer\u2019s disease: results of a randomized, double-blind,\n                    placebo-controlled phase 2a study","volume":"10","author":"P Scheltens","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a\n                    pilot study","volume":"33","author":"T Del Ser","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"S Lovestone","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for\n                    pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary\n                    degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"E Kontsekova","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active\n                    immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"P Novak","year":"2021","journal-title":"Nat Aging"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet\n                    Commission","volume":"396","author":"G Livingston","year":"2020","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1073\/pnas.0809158106","article-title":"Protection of synapses against Alzheimer\u2019s-linked toxins: insulin\n                    signaling prevents the pathogenic binding of Abeta oligomers","volume":"106","author":"F G De Felice","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of\n                    Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical\n                    Trial","volume":"77","author":"S Craft","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/alz.12137","article-title":"A randomized, controlled clinical trial of plasma exchange with albumin\n                    replacement for Alzheimer\u2019s disease: Primary results of the AMBAR\n                    Study","volume":"16","author":"M Boada","year":"2020","journal-title":"Alzheimers Dement"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1802-4837.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:29:21Z","timestamp":1719512961000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1802-4837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":49,"journal-issue":{"issue":"07\/08","published-online":{"date-parts":[[2022,7,20]]},"published-print":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1802-4837","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}